Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 7/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL89075 | 1.00 | HSD17B10 (0.47) | HSD17B10NR1H2ITGB3ITGA2BSMN1; SMN2 | |
| SCHEMBL90735 | 1.00 | HSD17B10 (0.47) | HSD17B10NR1H2ITGB3ITGA2BSMN1; SMN2 | |
| SCHEMBL90388 | 0.89 | HSD17B10 (0.46) | HSD17B10NR1H2ITGB3ITGA2BSMN1; SMN2 | |
| SCHEMBL89729 | 0.89 | HSD17B10 (0.46) | HSD17B10NR1H2ITGB3ITGA2BSMN1; SMN2 | |
| SCHEMBL89542 | 0.89 | HSD17B10 (0.46) | HSD17B10NR1H2ITGB3ITGA2BSMN1; SMN2 | |
| SCHEMBL23658046 | 0.89 | NR1H2 (0.43) | HSD17B10NR1H2SMN1; SMN2NAMPTMEN1 | |
| SCHEMBL17079714 | 0.89 | NR1H2 (0.43) | HSD17B10NR1H2SMN1; SMN2NAMPTMEN1 | |
| SCHEMBL29725741 | 0.89 | NR1H2 (0.43) | HSD17B10NR1H2SMN1; SMN2NAMPTMEN1 | |
| SCHEMBL18637510 | 0.89 | NR1H2 (0.43) | HSD17B10NR1H2SMN1; SMN2NAMPTMEN1 | |
| SCHEMBL90738 | 0.86 | NR1H2 (0.52) | HSD17B10NR1H2ITGB3ITGA2BSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-2420491-A1 | 3 , 5-substitued piperidine compounds as renin inhibitors | Novartis AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | HSD17B10 2045/4885NR1H2 1327/4885ITGB3 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.